SCHEDULE: RA Capital Management Discloses 9.1% Stake in Aclaris Therapeutics

RA Capital Management, along with affiliated entities and individuals, has reported a beneficial ownership of 9.1% of Aclaris Therapeutics' common stock as of June 30, 2026.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have collectively disclosed beneficial ownership of 12,723,026 shares of Aclaris Therapeutics, Inc. common stock.
• This holding represents 9.1% of the outstanding shares as of June 30, 2026.
• The filing is an amendment (Amendment No. 1) to a Schedule 13G.
• The reporting persons state that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but passive investment stake without immediate indications of activist intent.

Positives

• Significant investment by a notable healthcare-focused investment firm (RA Capital Management) indicates confidence in Aclaris Therapeutics' long-term prospects.
• The passive nature of the filing (Schedule 13G) suggests a non-activist investment strategy, which can be viewed positively by existing management and the market.

Negatives

• The filing does not provide any specific operational or financial performance data, making it difficult to assess the underlying business health.
• The disclaimer regarding beneficial ownership by RA Capital Management, Dr. Kolchinsky, and Mr. Shah, while standard for passive investors, highlights the complex structure of their holdings and potential for future shifts.

Risks

• While this filing is passive, a significant stake by RA Capital could potentially lead to future engagement or changes in strategy if the investment thesis evolves.
• The reliance on the issuer's reported outstanding shares (139,824,273 as of June 30, 2026) means any inaccuracies in that reporting could affect the reported percentage ownership.

Future Outlook

This filing is primarily a disclosure of ownership and does not contain forward-looking statements or specific guidance from Aclaris Therapeutics. The future outlook for the investment depends on RA Capital Management's ongoing strategy and Aclaris's business performance.

Management Comments

• The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G/A.
• RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.
• The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the shares of the Issuer's common stock reported herein.

Industry Context

StockSavvy.ai notes that RA Capital Management is a prominent investment firm known for its significant stakes in biotechnology and healthcare companies. Their passive filing suggests a belief in Aclaris Therapeutics' underlying value, aligning with broader investor interest in the pharmaceutical and biotechnology sectors, particularly in companies developing novel therapies.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a well-regarded investment firm may be viewed positively, potentially increasing investor confidence. However, the passive nature means no immediate strategic changes are implied.
• Management: The filing indicates a substantial passive investor, which generally does not directly impact day-to-day management unless the investor's strategy shifts.
• Creditors: No direct impact is indicated by this ownership disclosure.

Next Steps

• Continued monitoring of Aclaris Therapeutics' operational and financial performance.
• Observation of any future filings or communications from RA Capital Management regarding their stake.

Key Dates

Recommendation

The filing indicates a significant passive investment by RA Capital Management, suggesting confidence in Aclaris Therapeutics' long-term potential. However, without operational or financial performance data within this specific filing, and given the passive nature of the investment, a 'hold' recommendation is appropriate, pending further developments or performance updates from the company.

Keywords

Aclaris Therapeutics, RA Capital Management, Schedule 13G, Beneficial Ownership, Healthcare Fund, Investment Disclosure, Common Stock